April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
ApexOnco Front Page
Recent articles
Antibody-drug conjugates hitting this target abound.
The group could soon provide clarity on CTX112’s regulatory path.
The THIO-104 study listing is live, along with questions about funding the trial.
Against the odds, the CD47 inhibitor now faces two more clinical catalysts.
Golcadomide will begin a new pivotal trial in follicular lymphoma.
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
The company will soon start a pivotal trial of its IL-12 gene therapy, but cash is short.
